Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Duda

Showing results (311-320 of 338) with videos related to

Pageof 34
Sort By:
Science Translational Medicine|March 16, 2018
Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2Joao Incio, Jennifer A Ligibel, Daniel T McManus, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 2, 2021
Dendritic cell paucity in mismatch repair-proficient colorectal cancer liver metastases limits immune checkpoint blockade efficacyWilliam W Ho, Igor L Gomes-Santos, Shuichi Aoki, et al.
Endoscopic Ultrasound|June 29, 2019
Changes in tumor vascularity depicted by contrast-enhanced EUS as a predictor of prognosis and treatment efficacy in patients with unresectable pancreatic cancer (PEACE): A study protocolAdrian Sãftoiu, Manoop S Bhutani, Takao Itoi, et al.
Medrxiv : the Preprint Server for Health Sciences|October 17, 2024
Characterization of cell states in biliary tract cancers identifies mechanisms of therapeutic resistance in a phase II trial of DKN-01/nivolumabRyan J Park, Milan Parikh, Leon Pappas, et al.
Ebiomedicine|July 19, 2016
Tissue Microbiome Profiling Identifies an Enrichment of Specific Enteric Bacteria in Opisthorchis viverrini Associated CholangiocarcinomaKern Rei Chng, Sock Hoai Chan, Amanda Hui Qi Ng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2005
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patientsChristopher G Willett, Yves Boucher, Dan G Duda, et al.
Nature Medicine|January 28, 2004
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancerChristopher G Willett, Yves Boucher, Emmanuelle di Tomaso, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 6, 2013
Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiationTracy T Batchelor, Elizabeth R Gerstner, Kyrre E Emblem, et al.
Cancer|March 27, 2019
FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trialJames M Cleary, Nora K Horick, Nadine Jackson McCleary, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 5, 2016
Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survivalJonas Kloepper, Lars Riedemann, Zohreh Amoozgar, et al.
Pageof 34

Showing results (311-320 of 338) with videos related to

Sort By:
Pageof 34
Science Translational Medicine|March 16, 2018
Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2Joao Incio, Jennifer A Ligibel, Daniel T McManus, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 2, 2021
Dendritic cell paucity in mismatch repair-proficient colorectal cancer liver metastases limits immune checkpoint blockade efficacyWilliam W Ho, Igor L Gomes-Santos, Shuichi Aoki, et al.
Endoscopic Ultrasound|June 29, 2019
Changes in tumor vascularity depicted by contrast-enhanced EUS as a predictor of prognosis and treatment efficacy in patients with unresectable pancreatic cancer (PEACE): A study protocolAdrian Sãftoiu, Manoop S Bhutani, Takao Itoi, et al.
Medrxiv : the Preprint Server for Health Sciences|October 17, 2024
Characterization of cell states in biliary tract cancers identifies mechanisms of therapeutic resistance in a phase II trial of DKN-01/nivolumabRyan J Park, Milan Parikh, Leon Pappas, et al.
Ebiomedicine|July 19, 2016
Tissue Microbiome Profiling Identifies an Enrichment of Specific Enteric Bacteria in Opisthorchis viverrini Associated CholangiocarcinomaKern Rei Chng, Sock Hoai Chan, Amanda Hui Qi Ng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2005
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patientsChristopher G Willett, Yves Boucher, Dan G Duda, et al.
Nature Medicine|January 28, 2004
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancerChristopher G Willett, Yves Boucher, Emmanuelle di Tomaso, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 6, 2013
Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiationTracy T Batchelor, Elizabeth R Gerstner, Kyrre E Emblem, et al.
Cancer|March 27, 2019
FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trialJames M Cleary, Nora K Horick, Nadine Jackson McCleary, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 5, 2016
Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survivalJonas Kloepper, Lars Riedemann, Zohreh Amoozgar, et al.
Pageof 34